Regeneron’s Andrew J. Murphy sells 5,011 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Regeneron Pharmaceuticals, Inc. (REGN) Co-Chief Scientific Officer Andrew J. Murphy sold 5,011 common shares on November 17, 2026, at reported per-share prices ranging from $949.69 to $964.36. The sales were made pursuant to a plan intended to comply with Rule 10b5-1(c), adopted May 7, 2026. On November 16, he exercised options for 17,000 shares at $381.92 per share; 11,989 common shares were delivered or withheld for payment of exercise price or tax liability. The filing also lists 4,414 shares held indirectly through a 401(k) Plan.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 93 | $949.69 | $88K |
| Sale | Common Stock F1, F2 | 74 | $950.61 | $70K |
| Sale | Common Stock F1, F3 | 298 | $951.75 | $284K |
| Sale | Common Stock F1, F4 | 220 | $952.75 | $210K |
| Sale | Common Stock F1, F5 | 671 | $953.69 | $640K |
| Sale | Common Stock F1, F6 | 313 | $954.45 | $299K |
| Sale | Common Stock F1, F7 | 313 | $955.48 | $299K |
| Sale | Common Stock F1, F8 | 346 | $956.70 | $331K |
| Sale | Common Stock F1, F9 | 202 | $957.53 | $193K |
| Sale | Common Stock F1, F10 | 244 | $958.27 | $234K |
| Sale | Common Stock F1, F11 | 506 | $959.45 | $485K |
| Sale | Common Stock F1, F12 | 257 | $960.65 | $247K |
| Sale | Common Stock F1, F13 | 584 | $961.45 | $561K |
| Sale | Common Stock F1, F14 | 295 | $962.70 | $284K |
| Sale | Common Stock F1, F15 | 255 | $963.60 | $246K |
| Sale | Common Stock F1, F16 | 340 | $964.36 | $328K |
| Exercise | Non-Qualified Stock Option (right to buy) F1, F17 | 17,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 17,000 | $381.92 | $6.49M |
| Exercise Price or Tax Liability | Common Stock F1 | 11,989 | $960.02 | $11.51M |
| Holding | Common Stock | -- | -- | -- |
Footnotes (17)
- F1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026.
- F2. Represents volume-weighted average price of sales of 74 shares of Company stock on November 17, 2026 at prices ranging from $950.50 to $950.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F3. Represents volume-weighted average price of sales of 298 shares of Company stock on November 17, 2026 at prices ranging from $951.41 to $951.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F4. Represents volume-weighted average price of sales of 220 shares of Company stock on November 17, 2026 at prices ranging from $952.54 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F5. Represents volume-weighted average price of sales of 671 shares of Company stock on November 17, 2026 at prices ranging from $953.18 to $953.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F6. Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $954.26 to $954.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F7. Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $955.02 to $955.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F8. Represents volume-weighted average price of sales of 346 shares of Company stock on November 17, 2026 at prices ranging from $956.17 to $956.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price
- F9. Represents volume-weighted average price of sales of 202 shares of Company stock on November 17, 2026 at prices ranging from $957.00 to $957.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F10. Represents volume-weighted average price of sales of 244 shares of Company stock on November 17, 2026 at prices ranging from $958.12 to $958.44. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F11. Represents volume-weighted average price of sales of 506 shares of Company stock on November 17, 2026 at prices ranging from $959.03 to $959.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F12. Represents volume-weighted average price of sales of 257 shares of Company stock on November 17, 2026 at prices ranging from $960.10 to $960.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F13. Represents volume-weighted average price of sales of 584 shares of Company stock on November 17, 2026 at prices ranging from $961.07 to $961.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F14. Represents volume-weighted average price of sales of 295 shares of Company stock on November 17, 2026 at prices ranging from $962.17 to $962.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F15. Represents volume-weighted average price of sales of 255 shares of Company stock on November 17, 2026 at prices ranging from $963.28 to $963.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F16. Represents volume-weighted average price of sales of 340 shares of Company stock on November 17, 2026 at prices ranging from $964.03 to $964.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
- F17. The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Key Figures
Key Terms
Rule 10b5-1(c) regulatory
volume-weighted average price financial
Non-Qualified Stock Option technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many REGN options did Andrew J. Murphy exercise?
AI-generated analysis. How Rhea-AI works. Not financial advice.